http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Alnylam Pharma (ALNY) Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
-
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
-
Alnylam Pharma (ALNY) Submits Regulatory Applications to FDA and EMA to Support Label Expansion for OXLUMO for Treatment of Advanced Primary Hyperoxaluria Type 1
-
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxalur
-
Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021
-
Alnylam to Webcast Presentations at Upcoming Investor Conferences
-
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
-
Alnylam Pharma (ALNY) Reports New Phase 1 Data for Zilebesiran
-
Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021
-
Alnylam to Webcast Virtual R&D Day
-
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
-
Alnylam Pharma (ALNY) Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
-
Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
-
Alnylam Named a Science Magazine Top Employer for Third Consecutive Year
-
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
-
Alnylam Pharma (ALNY) Announces Planned Retirement of CEO John Maraganore
-
Alnylam Announces Planned CEO Leadership Transition
-
Alnylam Pharma (ALNY) Announces Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran
-
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
-
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
-
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
-
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
-
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
-
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
-
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
-
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
-
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
-
Alnylam Pharma (ALNY) Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
-
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
-
Alnylam to Webcast Conference Call Discussing Second Quarter 2021 Financial Results
-
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
-
Alnylam Pharma (ALNY) Announces FDA Acceptance of NDA for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
-
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
-
Alnylam to Host Eighth Annual “RNAi Roundtable” Webcast Series
-
Alnylam Pharma (ALNY) Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
-
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
-
Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy
-
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
-
Alnylam Pharma (ALNY) Announces New Advances in ATTR Amyloidosis Program
-
Alnylam Announces New Advances in ATTR Amyloidosis Program
-
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
-
Alnylam Pharma (ALNY) Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO
-
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
-
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
-
Alnylam Pharma (ALNY) Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
-
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
-
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
-
Alnylam Pharma (ALNY) Announces Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT
-
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
-
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
